APOB and coronary artery disorder: Quantification of apolipoproteins A and B provides a measure of the total number of anti-atherogenic and pro-atherogenic particles in plasma.61 The Quebec Heart study demonstrated accelerated CAD in patients with hyperapolipoproteinaemia-B.62 Our study also showed a significant rise in the atherogenic apolipoprotein B levels in AMI patients in the atherosclerosis-prone North Indian population, compared with control subjects, and indicates that the measurement of apo-B concentration can more accurately delineate coronary artery disease than LDL cholesterol measurement alone.